---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-066276"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:23:12.662155+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences: Draft Medicare LCDs propose no coverage restrictions for OMNI and SION

## Summary
- Five MACs published draft LCDs on MIGS not proposing specific coverage criteria for OMNI (canaloplasty+trabeculotomy) or SION (goniotomy).
- These procedures would remain eligible for Medicare in states covering 62% of Sight Sciences' 2023 Surgical Glaucoma revenue.
- Draft LCDs propose non-coverage when an aqueous shunt/stent is performed with a MIGS procedure in the same eye at same time.
- 45-day comment period; finalization within 365 days. Company plans to engage with MACs, CMS, and clinical societies.

## SEC filing metadata
- accession: 0000950170-24-066276
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017024066276/0000950170-24-066276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017024066276/sght-20240530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-066276
- JSON: https://secwatch.observer/filing/0000950170-24-066276.json
- Plain text: https://secwatch.observer/filing/0000950170-24-066276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.